Robeco Institutional Asset Management
FPRX

Robeco Institutional Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Robeco Institutional Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-62,879
Closed -$2.27M – 898
2017
Q1 		$2.27M Buy
+62,879
New +$2.77M 0.02% 561

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Robeco Institutional Asset Management's FPRX Position: Q2 2017 in Review

Robeco Institutional Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 62,879 shares — an estimated $2.27M sold.

Robeco Institutional Asset Management first reported a position in FPRX in Q1 2017 and held it in 1 quarter. The position peaked at $2.27M in Q1 2017. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Robeco Institutional Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 62,879 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $2.27M.
  • Robeco Institutional Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Robeco Institutional Asset Management's Five Prime Therapeutics, Inc. position peaked at $2.27M in Q1 2017.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2017, filed 8 Aug 2017.